Inflammopharmacology · 2025
A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heidari Amirhossein, Fathabadi Fatemeh, Ghanavati Kimia, Rasouli Asma, Soleimani Sanaz, Heidari Nazila
Аннотация
BACKGROUND: Lichen planus (LP) is a group of chronic inflammatory disorders of the skin, mucous membranes, scalp, and nails that mainly affect the middle-aged population. Inflammatory modifiers, including interferon-α (IFN-α), IFN-γ, tumor necrosis factor-alpha (TNF-α), as well as various interleukins (ILs), such as IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, IL-21, IL-22, and IL-23 has also been suggested to contribute in the LP pathogenesis. We aim to systematically evaluate the effect of IL inhibitors on treating and triggering LP disease.
METHODS: A systematic search was conducted up to January 30th, 2025, in PubMed/Medline, Web of Science, and Ovid-Embase, and clinical studies with available English full-text were included.
RESULTS: The search recorded 196 relevant studies, with 42 articles eligible for this study. IL-inhibitors, including dupilumab, secukinumab, anakinra, tildrakizumab, guselkumab, ustekinumab, ixekizumab, risankizumab, and brodalumab were associated with clinical improvement in various types of LP. In contrast, in some cases with a coexistent autoimmune disease, such as psoriasis and atopic dermatitis, secukinumab, dupilumab, risankizumab, ustekinumab, and ixekizumab administration resulted in LP development.
CONCLUSION: IL inhibitors demonstrate both treatment and paradoxical effects on LP. Further research is needed to elucidate the impact of these agents on the pathophysiology of LP.
METHODS: A systematic search was conducted up to January 30th, 2025, in PubMed/Medline, Web of Science, and Ovid-Embase, and clinical studies with available English full-text were included.
RESULTS: The search recorded 196 relevant studies, with 42 articles eligible for this study. IL-inhibitors, including dupilumab, secukinumab, anakinra, tildrakizumab, guselkumab, ustekinumab, ixekizumab, risankizumab, and brodalumab were associated with clinical improvement in various types of LP. In contrast, in some cases with a coexistent autoimmune disease, such as psoriasis and atopic dermatitis, secukinumab, dupilumab, risankizumab, ustekinumab, and ixekizumab administration resulted in LP development.
CONCLUSION: IL inhibitors demonstrate both treatment and paradoxical effects on LP. Further research is needed to elucidate the impact of these agents on the pathophysiology of LP.